Eculizumab for treatment of thrombotic microangiopathy secondary to systemic lupus erythematosus in children: two cases report and literature review
10.3760/cma.j.cn441217-20230504-00502
- VernacularTitle:伊库珠单抗治疗儿童系统性红斑狼疮合并血栓性微血管病的2例经验分享及文献复习
- Author:
Lingxia ZHANG
1
;
Jingjing WANG
;
Yanyan JIN
;
Fei LIU
;
Haidong FU
;
Bingrong CHEN
;
Jianhua MAO
Author Information
1. 浙江大学医学院附属儿童医院肾内科，儿童健康与疾病国家临床医学研究中心，浙江省儿童非感染性慢病研究重点实验室，杭州 310053
- Keywords:
Child;
Lupus erythematosus, systemic;
Thrombotic microangiopathies;
Eculizumab;
Treatment
- From:
Chinese Journal of Nephrology
2023;39(12):942-946
- CountryChina
- Language:Chinese
-
Abstract:
Systemic lupus erythematosus (SLE) is a serious autoimmune disease that affects multiple systems and organs throughout the body. Thrombotic microangiopathy (TMA) is a rare clinical syndrome that can lead to multiple organ dysfunction and even threaten life. Clinically, SLE patients with TMA are relatively rare, especially in children, but the mortality of SLE patients with TMA is significantly increased. The article reports 2 cases of successful remission of SLE complicated with TMA after treatment with eculizumab, and discusses the diagnosis, clinical manifestations and treatment of SLE complicated with TMA in children, so as to provide clinical basis for the diagnosis and treatment of SLE complicated with TMA in children.
